TY - JOUR
T1 - Considerations for endpoint selection when designing HIV clinical trials
AU - Hullsiek, Katherine Huppler
AU - Grund, Birgit
PY - 2012/2/1
Y1 - 2012/2/1
N2 - Selecting the primary endpoint is one of the most important decisions in designing clinical trials. Many HIV trials are powered for surrogate markers, often virologic suppression. Among 49 recently published Phase 3 or higher randomized HIV trials only 14% were powered for clinical outcomes such as the progression to AIDS, death, or serious non-AIDS diseases. We provide two examples where interventions modified the targeted surrogate markers but failed to provide clinical benefit. We review the use of surrogate and clinical endpoints, discuss the composition of clinical endpoints, and the need for endpoint verification. In HIV-infected individuals with CD4 cell counts above 200 cells/mm 3 serious non-AIDS conditions such as cardiovascular, renal, hepatic diseases and cancer contribute substantially to morbidity and mortality. In this population clinical endpoint trials should be powered for non-AIDS morbidity along with AIDS.
AB - Selecting the primary endpoint is one of the most important decisions in designing clinical trials. Many HIV trials are powered for surrogate markers, often virologic suppression. Among 49 recently published Phase 3 or higher randomized HIV trials only 14% were powered for clinical outcomes such as the progression to AIDS, death, or serious non-AIDS diseases. We provide two examples where interventions modified the targeted surrogate markers but failed to provide clinical benefit. We review the use of surrogate and clinical endpoints, discuss the composition of clinical endpoints, and the need for endpoint verification. In HIV-infected individuals with CD4 cell counts above 200 cells/mm 3 serious non-AIDS conditions such as cardiovascular, renal, hepatic diseases and cancer contribute substantially to morbidity and mortality. In this population clinical endpoint trials should be powered for non-AIDS morbidity along with AIDS.
KW - Clinical endpoint
KW - Clinical trial design
KW - Endpoint verification
KW - HIV clinical trials
KW - Non-AIDS endpoint
KW - Primary endpoint selection
KW - Surrogate endpoint
UR - http://www.scopus.com/inward/record.url?scp=84857639343&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857639343&partnerID=8YFLogxK
U2 - 10.1007/s11908-011-0231-7
DO - 10.1007/s11908-011-0231-7
M3 - Review article
C2 - 22161272
AN - SCOPUS:84857639343
VL - 14
SP - 110
EP - 118
JO - Current Infectious Disease Reports
JF - Current Infectious Disease Reports
SN - 1523-3847
IS - 1
ER -